Venmax Drugs & Pharmaceuticals Ltd.
|BSE: 531015||Sector: Health care|
|NSE: N.A.||ISIN Code: INE154G01022|
|BSE 16:01 | 19 Mar||Venmax Drugs & Pharmaceuticals Ltd|
|NSE 05:30 | 01 Jan||Venmax Drugs & Pharmaceuticals Ltd|
Venmax Drugs & Pharmaceuticals Ltd. (VENMAXDRUGS) - News Sector
8.27 pm | 27 May 2022 | Business Standard
Based on sum-of-the-parts valuation, some analysts have pegged their target price between Rs 4,900-5,000
11.06 am | 27 May 2022 | Business Standard
The stock has fallen below its previous low of Rs 1,688, touched on May 27, 2021
1.10 am | 27 May 2022 | Business Standard
Board recommends a dividend of Rs 33 per share, subject to shareholder's approval.
11.41 pm | 26 May 2022 | Business Standard
Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market resear...
11.34 am | 26 May 2022 | Business Standard
The company said the macro environment continues to be challenging due to volatility in costs and disruptions across supply chains.
9.38 am | 26 May 2022 | Business Standard
In Q4, the company posted net loss of Rs 118 crore against profit of Rs 324 crore in the year ago quarter
11.37 pm | 25 May 2022 | Business Standard
The red line comes amid headwinds in EU operatopns and discontinuation of liquids business in the US; revenue, however, grows by 10%
7.42 am | 25 May 2022 | Business Standard
Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospital...
10.02 am | 24 May 2022 | Business Standard
The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity ...
12.45 am | 21 May 2022 | Bloomberg
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
11.33 pm | 20 May 2022 | Business Standard
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
11.31 pm | 20 May 2022 | Business Standard
Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
2.33 pm | 20 May 2022 | Business Standard
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
1.08 am | 20 May 2022 | Business Standard
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
12.55 am | 20 May 2022 | Business Standard
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions